Oncogenic mutations in ESR1 are common in metastatic and pretreated breast cancer, emerging as a mechanism of acquired resistance to endocrine therapies that can ultimately result in a lack of response to the combinational therapy [61]. The gene discussed is ESR1; the disease is breast cancer.